New hope for Hard-to-Treat ovarian cancer: drug combo shows promise
NCT ID NCT04055649
First seen Jun 18, 2026 · Last updated Jun 18, 2026
Summary
This study tests a new drug called ONC201 combined with the chemotherapy paclitaxel in people with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. The goal is to see if the combination is safe and works better than paclitaxel alone. About 62 participants will receive the treatment, and researchers will monitor side effects and tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Ann Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact Phone: •••-•••-••••
Contact
Contact
Contact
-
Karmanos Cancer Institute at McLaren Flint
RECRUITINGFlint, Michigan, 48532, United States
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.